Health & Food
Prostate cancer drug rejected by FDA panel
WASHINGTON (KABC) -- A federal panel rejected the use of a new drug for prostate cancer because it could do more harm than good.
The Food and Drug Administration panel said the risk of Merck's Proscar causing patients to develop more aggressive tumors outweighed any benefit it had on low-grade tumors, which are less often fatal.
Studies showed the drug to reduce low-grade tumors by 25 percent, but a small number of men actually developed more aggressive tumors.
GlaxoSmithKline is set to present a similar drug for approval in the near future.
The FDA is not required to follow the recommendations of the panel but usually does.
cancer, men's health, medical research, health & food
- LAPD Officer Lee honored at funeral service
- 2 dead after car plows through SXSW crowd
- NYC explosion kills 7; rescuers resume search
- OC high-speed chase ends in police shooting
- Inmate escapes jail hours after sentencing
- Ex-assemblyman arrested for domestic violence
- Flasher sought for exposing self at Brea Mall 12 min ago
- Ex-Manson follower granted parole for 3rd time
- Man in Fla. theater shooting also was texting 6 min ago
- Malaysia plane search widens toward India
- abcnews: Amazon accused of cheating on free shipping
- Soldier pops out of box, surprises daughter
- Elderly couple's dog saved by rescue group
- OTRC: Elizabeth Olsen engaged, report says